Abiraterone Acetate

• Capivasertib + Abiraterone as Treatment for Patients with Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency (CAP… Ended
  2023-504998-20-00 Phase III 9 countries AstraZeneca AB
• Investigation of Radium-223 dichloride (Xofigo), a treatment that gives off radiation that helps kill cancer cells, compared to a treatment … Ended
  2023-505830-89-00 Phase IV 10 countries Bayer AG; Bayer Consumer Care AG
• A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended
  2023-503254-12-00 Phase III 10 countries Janssen - Cilag International
• B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and… Ended
  2023-505509-18-00 Phase III 7 countries Universitaetsklinikum Muenster AöR
• An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Ended
  2023-508606-26-00 Phase III 3 countries Janssen Cilag International
• A Clinical study to assess the safety and effectiveness of ARN-509 in men with Castration-Resistant Prostate Cancer (prostate cancer not res… Ended
  2023-509221-47-00 Phase III 12 countries Aragon Pharmaceuticals Inc.
• Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants with Congenital Adrenal Hyperplasia Ended
  2023-503488-40-00 Phase II 2 countries Crinetics Pharmaceuticals Inc.
• A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma Ended
  2023-503348-15-00 Phase I (FiH) 5 countries Genmab A/S

Showing 25–32 of 32 trials